Pfizer Inc. (NYSE:PFE) Shares Bought by Jackson Hole Capital Partners LLC

Jackson Hole Capital Partners LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,415 shares of the biopharmaceutical company’s stock after acquiring an additional 3,342 shares during the period. Jackson Hole Capital Partners LLC’s holdings in Pfizer were worth $2,603,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atwater Malick LLC lifted its position in shares of Pfizer by 1.2% during the 3rd quarter. Atwater Malick LLC now owns 165,839 shares of the biopharmaceutical company’s stock worth $5,501,000 after buying an additional 1,964 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its position in shares of Pfizer by 21.2% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 14,506 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 2,534 shares during the last quarter. Willis Investment Counsel lifted its position in shares of Pfizer by 4.6% during the 3rd quarter. Willis Investment Counsel now owns 1,070,451 shares of the biopharmaceutical company’s stock worth $35,507,000 after buying an additional 47,517 shares during the last quarter. Berkshire Money Management Inc. raised its position in Pfizer by 3.5% in the 3rd quarter. Berkshire Money Management Inc. now owns 22,263 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 750 shares during the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its position in Pfizer by 3.5% in the 3rd quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 34,283 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 1,165 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Price Performance

Shares of NYSE:PFE traded down $1.01 on Thursday, reaching $25.26. 47,041,425 shares of the company were exchanged, compared to its average volume of 41,958,969. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The firm has a market cap of $143.04 billion, a price-to-earnings ratio of 70.17, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. The company has a 50-day moving average of $27.01 and a 200-day moving average of $28.48.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.14 EPS. Equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.65%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.